^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Y150

    i
    Other names: Y150
    Associations

    News

    Trials
    Company:
    YZY Biopharma
    Drug class:
    CD3 agonist, CD38 inhibitor
    Related drugs:
    Associations

    News

    Trials
    4ms
    A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=20, Completed, Wuhan YZY Biopharma Co., Ltd. | Recruiting --> Completed | N=75 --> 20
    Trial completion • Enrollment change
    |
    Y150